Immucell (ICCC) Current Deferred Revenue (2011 - 2018)

Immucell's (ICCC) quarterly Current Deferred Revenue came in at $24100.0 in Q3 2018, little changed on a QoQ basis from $24100.0 in Q2 2018.

Immucell (ICCC) Current Deferred Revenue (2011 - 2018) Analysis & Trends

Immucell (ICCC) has 8 years of Current Deferred Revenue data on file, last reported at $24100.0 in Q3 2018.

Quarterly Current Deferred Revenue changed N/A year-over-year to $24100.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $24100.0 (changed N/A YoY) and the FY2017 annual result came in at $24100.0, down 28.82% from the prior year.
Current Deferred Revenue was little changed at $24100.0 in Q3 2018, from $24100.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $33856.0 in Q3 2016 to a low of $6690.0 in Q3 2014.
A 5-year average of $20464.7 and a median of $24100.0 in 2017 frame the typical range for Current Deferred Revenue.
The widest YoY moves for Current Deferred Revenue: up 28.82% in 2017, down 28.82% in 2017.
Tracing ICCC's Current Deferred Revenue over 5 years: stood at $6690.0 in 2014, then changed by 0.0% to $6690.0 in 2015, then soared by 406.07% to $33856.0 in 2016, then retreated by 28.82% to $24100.0 in 2017, then changed by 0.0% to $24100.0 in 2018.
The last three Current Deferred Revenue figures came in at $24100.0 (Q3 2018), $24100.0 (Q2 2018), and $24100.0 (Q1 2018), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Immucell	91.19 Mn	82.33 Mn	2.44 Mn

Download Data